Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

AAA Biotech Launches Validated Antibodies & Research Reagents Browse AAA Biotech's new range of validated antibodies, ELISA kits, and cultu ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

Researchers create nanomachines using metal and polyphenols, which enhance targeted intracellular delivery of antibodies for ...

A breakthrough in cancer therapy: metal-phenolic nanocarriers deliver antibodies directly to cancer cells, improving ...

In a significant step towards improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...